{"filing":{"accession_number":"0001213900-26-098213","cik":"0001873875","ticker":"IXHL","company_name":"Incannex Healthcare Inc.","form":"8-K","filing_date":"2026-09-09","report_date":"2026-09-09","primary_document":"ea0304782-8k_incannex.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1873875/000121390026098213/ea0304782-8k_incannex.htm"},"events":[{"id":32184,"run_id":29566,"accession_number":"0001213900-26-098213","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The filing discloses multiple operational and clinical milestones for a clinical-stage biopharmaceutical company: commencement of patient dosing in the DReAMzz Phase 2 study of IHL-42X for obstructive sleep apnea, grant of a U.S. composition patent extending to 2040, and a strong cash position of approximately $70 million with no debt. While the press release covers clinical progress, intellectual property, and financial position, the core event is the advancement of the company's drug development pipeline and operational progress rather than a specific financial transaction, governance change, or other named event type. This is material to investors assessing the registrant's clinical and operational trajectory.","company_name":"Incannex Healthcare Inc.","ticker":"IXHL","filing_date":"2026-09-09","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":35295,"accession_number":"0001213900-26-098213","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses multiple operational and clinical milestones for a clinical-stage biopharmaceutical company: commencement of patient dosing in the DReAMzz Phase 2 study of IHL-42X for obstructive sleep apnea, grant of a U.S. composition patent extending to 2040, and a strong cash position of approximately $70 million with no debt. While the press release covers clinical progress, intellectual property, and financial position, the core event is the advancement of the company's drug development pipeline and operational progress rather than a specific financial transaction, governance change, or other named event type. This is material to investors assessing the registrant's clinical and operational trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T11:31:50.636310+00:00","company_name":"Incannex Healthcare Inc.","ticker":"IXHL","filing_date":"2026-09-09"}]}